Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Infigratinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BridgeBio data show sustained benefit for achondroplasia drug
    BridgeBio data show sustained benefit for achondroplasia drug

    05 Jun 2024

    // Ned Pagliarulo BIOPHARMADIVE

    https://www.biopharmadive.com/news/bridgebio-infigratinib-achondroplasia-propel-study-results/717914/

    Ned Pagliarulo BIOPHARMADIVE
    05 Jun 2024
    Share Share
    BridgeBio: Durable Infigratinib Results In Achondroplasia Study
    BridgeBio: Durable Infigratinib Results In Achondroplasia Study

    04 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/04/2892934/0/en/BridgeBio-Announces-Durable-Month-12-and-18-Phase-2-Cohort-5-Results-of-Oral-Infigratinib-in-Achondroplasia-and-First-Participant-Consented-in-ACCEL-for-Hypochondroplasia.html

    GLOBENEWSWIRE
    04 Jun 2024
    Share Share
    BridgeBio To Host Infigratinib Achondroplasia Phase 2 Data Call
    BridgeBio To Host Infigratinib Achondroplasia Phase 2 Data Call

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892563/0/en/BridgeBio-to-Host-Call-on-Month-12-and-18-Phase-2-Cohort-5-Results-of-Oral-Infigratinib-in-Achondroplasia-on-June-4-2024.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    WITHDRAWN: FDA accelerated approval to infigratinib for metastatic cholangiocarcinoma
    WITHDRAWN: FDA accelerated approval to infigratinib for metastatic cholangiocarcinoma

    18 May 2024

    // FDA

    https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma#:~:text=On%20May%2028%2C%202021%2C%20the,2%20(FGFR2)%20fusion%20or%20other

    FDA
    18 May 2024
    Share Share
    For $100M, BridgeBio partners with Kyowa Kirin on infigratinib
    For $100M, BridgeBio partners with Kyowa Kirin on infigratinib

    07 Feb 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/kyowa-kirin-pays-100m-partner-bridgebio-potential-dwarfism-drug

    FIERCE PHARMA
    07 Feb 2024
    Share Share
    BridgeBio Announces First Child Dosed in Phase 3 Clinical Trial for Infigratinib
    BridgeBio Announces First Child Dosed in Phase 3 Clinical Trial for Infigratinib

    13 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/13/2795471/0/en/BridgeBio-Announces-First-Child-Dosed-in-PROPEL-3-its-Phase-3-Clinical-Trial-for-Infigratinib-in-Children-with-Achondroplasia.html

    GLOBENEWSWIRE
    13 Dec 2023
    Share Share